Sat, Aug 30, 2014, 10:10 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

IGO, INC Message Board

gswkool 44 posts  |  Last Activity: 8 hours ago Member since: Jan 2, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • it's cheap because the platform is unproven and it appears to be a fringe player in the space it is playing in. Positive results in a large trial will have significant impact on share price and enable the company to raise money more cheaply. Negative results and its goose is cooked....IMHO....GLTA

  • Reply to

    PDUFA on Sept. 26

    by yoda_camel Aug 27, 2014 9:45 AM
    gswkool gswkool Aug 27, 2014 12:42 PM Flag

    if it was a done deal they would have approved it already. I think the fda needs to evaluate the updated data package which includes data out of Europe. my guess is they will deliberate on the 26th and we will get a determination then.....just my guess....I won't put any odds on whether its approved or not....I will say that I am a stock holder in psdv shares..............

  • gswkool gswkool Aug 24, 2014 6:52 PM Flag

    FDA has to weigh risk/benefit. Since it is a treatment of last resort, it is not competing with the anti-VEGF drugs approved by FDA. As there is some % of patients that do not respond to anti-VEGF drugs, as long as Lluvien shows some benefit in the data submitted I think it has a decent shot at approval. Not sure what I would do as an investor in the stock if it was denied. If it is approved, I will wait 'til the price settles down and probably buy more shares. Personally, got a good feeling about PSDV but one never knows....don't buy what you can't afford to lose.......GLTA

  • gswkool gswkool Aug 11, 2014 9:39 PM Flag

    the problem in my impression is that it was not in as good hands with GERN. Otherwise, they would be in a better position to satisfy the FDA. Mayo and DR.T was able to satisfy FDA. Certainly it is good that he is gonna be coordinating things. However, he has the task of collecting data which GERN should have been tracking in first place, and it may not be possible to put humpty dumpty back together again. As a shareholder, I hope he succeeds. Otherwise my money is down the toilet. My confidence is not so high, even with Dr. T's help. We'll see.....

  • gswkool gswkool Jul 25, 2014 6:01 PM Flag

    I think the market has topped or is very close. That doesn't mean a free fall, however, - Unless there is some big event, the downtrend could occur in a more subtle manner over a period of time. There will be few good places to hide. Speculative biotechs don't have earnings or dividends holding them up. So they will fall. However, any positive news coming out of a speculative biotech will certainly trump market conditions -in a big way or at least for a time, depending on magnitude of the news. That's my take....GLTA

  • gswkool gswkool Jul 25, 2014 5:49 PM Flag

    I hear what you're saying. One big difference btw. the two is that Ozurdex is biodegradeable. If you are a patient and there are risks of side effects from the implant -one has to be injected more frequently but disappears in the end, and the other stays in your eye forever but has to be injected less frequently - which would you choose if efficacy is similar? I have PSDV shares but as a patient I'd be more inclined to go with the bioerodable version i.e. Ozurdex. It would be interesting to get the opinion of someone in the field. I also wonder how this will play into the looming FDA decision. Allergan just got approval in Europe. In US, Ozurdex already approved.

  • It has a drug and an aptimer. So potential is there for allegic reaction to either/or as opposed to single entity. Additionally, is it possible that the interaction btw the two can be an issue for some? I have no idea what the outcome of the findings will be - sold my shares on the news and took the tax loss. It should be interesting, though. The safest way to play this may be with options - anyone look into that?

  • seems to be limping along, -very little news flow. wake me up when something interesting happens...i'd say 6 months or so...

  • Reply to

    Guesses on sp of PSDV after 26 Sep??

    by aussiefrank55 Jul 23, 2014 4:37 PM
    gswkool gswkool Jul 25, 2014 10:33 AM Flag

    I'm probably overly optimistic, but that's just me. In terms of FDA approval, Tethadur is still preclinical so I would think it's off the radar of FDA. I realize the stock market is tainted, but I wouldn't know how to factor in such a hypothesis as the one you stated. I'm not so sure how long it will take for PSDV to actually earn money from Lluvien itself - the immediate $25M gratification is what I am looking forward to......

  • OZURDEX (dexamethasone 700 mcg intravitreal implant in applicator) is biodegradeable implant. Already approved by FDA I believe. Anyone know how it stacks up vs Lluvien?

  • gswkool gswkool Jul 24, 2014 9:36 AM Flag

    you're right....pretty sad...if they were for real they would be paying a dividend to reward investors, -the stock does look cheap here on technical basis though - this is a stock to trade and not to hold.... as you say, it's the insiders that will continue to profit on a long term basis....

  • Reply to

    Guesses on sp of PSDV after 26 Sep??

    by aussiefrank55 Jul 23, 2014 4:37 PM
    gswkool gswkool Jul 24, 2014 9:24 AM Flag

    I'd say you're close. Approval has multiple implications -better cash position from which to negotiate deals from, faster approval path for medidur, increased exposure to investor and analyst community from positive news and SP appreciation, as well as the obvious.... So, my guess is $8-9 on the announcement approval.
    On the downside, if rejected, $2.5 -$3.00 ......IMHO.....GLTA

  • Reply to

    FovistaTM Anti-PDGF Therapy

    by gswkool Jul 21, 2014 8:32 PM
    gswkool gswkool Jul 22, 2014 10:22 AM Flag

    Mick, thanks for the reply. I believe Novartis is or will be working on a combination drug i.e. whereby they can be delivered together. I am wondering if Tethadur will be able to deliver this combination drug - of course all this is a ways off. Just found it interesting. I think OPHT is looking at 2016 for possible approval of Fovista. Note that the Novartis deal, which was quite lucrative, was for Int'l rights only. OPHT kept US for themselves so far. I do think Fovista approval could have some level of negative implications for Lluvien, but not overly concerned -looking forward to the $25M payment which will be extremely helpful for PSDV........

  • FovistaTM is designed to target platelet derived growth factor (PDGF) in combination with anti-VEGF drugs to disrupt the formation of abnormal new blood vessels in wet AMD. In clinical trials, the combination of FovistaTM 1.5mg and an anti-VEGF therapy demonstrated statistically significant superiority compared to anti-VEGF monotherapy in terms of improvements in visual acuity, providing a 62% comparative benefit from baseline

    Company is symbol OPHT......they are not targeting a specific anti-vegf therapy; rather, they are targeting it to work with any approved anti-vegf therapy.......

  • Reply to

    stock price starting to move

    by gswkool Jun 28, 2014 11:35 AM
    gswkool gswkool Jul 21, 2014 8:23 PM Flag

    quarterly report was not so good. Not impressed on choco side of things. Demand is increasing for chocolate worldwide as middle class grows internationally. However, this will push up price of cocoa. RMCF too small -it's not nestle or hershey. So it may have problems with margins when cocoa price moves higher. They should divest choco business and go with yogurt. ....

  • gswkool by gswkool Jul 19, 2014 5:50 PM Flag

    Check out the company for symbol OPHT. Over billion dollar market cap. Got a great partnering deal. How does this bode for potential Lluven sales....? well, hopefully there will still be some market left....and $25M is $25M if it is approved....

    FovistaTM Anti-PDGF Therapy

    FovistaTM is designed to target platelet derived growth factor (PDGF) in combination with anti-VEGF drugs to disrupt the formation of abnormal new blood vessels in wet AMD. In clinical trials, the combination of FovistaTM 1.5mg and an anti-VEGF therapy demonstrated statistically significant superiority compared to anti-VEGF monotherapy in terms of improvements in visual acuity, providing a 62% comparative benefit from baseline.

  • Reply to

    Just A Guess On Roche

    by mickmack50 Jul 14, 2014 9:16 AM
    gswkool gswkool Jul 14, 2014 12:25 PM Flag

    Provided Lluvien gets approval in the U.S., why would anyone wish for a takeover? PSDV is far from reaching its potential. With $25M additional in the bank, they can continue to progress for the foreseeable future. The last thing I would want to see is a sellout . I'm not one for instant gratification. Anyhow, a little over eight weeks to go before a decision. If it goes against PSDV, then it will be time to reevaluate....GLTA

  • Reply to

    stock price starting to move

    by gswkool Jun 28, 2014 11:35 AM
    gswkool gswkool Jul 12, 2014 10:51 AM Flag

    better late than never. expect more progress on the yogurt front. so much for chocolate biz -progress there has been a dud.....

  • Reply to

    VERY FAVORABLE RISK/REWARD HERE BUY WITH BOTH FISTS

    by erp3359 Jun 29, 2014 4:13 PM
    gswkool gswkool Jul 12, 2014 9:44 AM Flag

    weeks or months to wait - not a big deal. I'll be happy if it happens before EOY. Still plenty of money to be made by/on MNTA. ...

  • gswkool gswkool Jul 6, 2014 10:58 AM Flag

    Markets will only be as rational as the people that participate in them. How many rational people do you know? How many rational people do you know that invest in the market? Most people don't have a clue...

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Burger King Worldwide, Inc.
NYSEFri, Aug 29, 2014 4:02 PM EDT
Synaptics Inc.
NasdaqGSFri, Aug 29, 2014 4:00 PM EDT